Stage 1

Area: 13,000 m2
Annual production capacity:
100 million doses

Stage 2

Area: 15,000 m2
Annual production capacity:
200 - 300 million doses

After more than 20 years without vaccine or biological production in Colombia, VaxThera seeks to build the technological and scientific capabilities to position the country as a science and technology hub.

To achieve this, in 2024 we inaugurated our vaccine and biologics production facility, located in Rionegro, Antioquia. In 2025, we began the GMP (Good Manufacturing Practices) certification processes with Invima, COFEPRIS, FDA, and EMA.

The facility includes spaces for formulation, fill and finish, production, potency testing, and a research and development unit.

The construction of each phase will be supported by ethical and environmental considerations, responsible waste management, and other practices in favor of environmental care.

VaxThera Plant

Quality statement

Quality is the cornerstone of VaxThera's mission in providing vaccines and therapeutics. We are committed to continuously improving our processes and ensuring their consistency and robustness in the manufacturing and supply of our products. We take pride in cultivating a culture of unwavering quality throughout our organization, ensuring that every product we supply meets the global standards and regulatory requirements. We understand that the health and well-being of countless individuals depend on the quality of our products, and we strive every day to ensure the customer satisfaction.

Global Impact

Our manufacturing plant will have the capacity to supply not only Colombia but also other countries in the region. We aim to contribute to public health worldwide.

Technology Transfer

VaxThera has partnerships with renowned pharmaceutical companies in India, the United States, Europe, and Latin America to carry out co-development and technology transfer. Our pipeline includes vaccines from the Expanded Program on Immunization (e.g., influenza, pentavalent, polio), monoclonal antibodies, gene therapies, and recombinant proteins.